In mid-2025, a &#34;industry-level public opinion controversy&#34; with Bloomage Biotech pushed GIANT BIOGENE to the forefront.
This dispute was not only a struggle for discourse power in the reorganization of collagen and hyaluronic acid, but also embroiled GIANT BIOGENE in a public opinion whirlpool regarding the false labeling of collagen content in its core brand &#34;Kefumei.&#34;
Although this storm ultimately concluded with differing test results due to varying testing standards, it did have a certain impact on GIANT BIOGENE's performance.
Combined with increasingly fierce industry competition, GIANT BIOGENE delivered a 2025 report card showing declines in both revenue and profit: the revenue for the period was 5.518 billion yuan, a slight decrease of 0.37% year-on-year, and net profit was 1.914 billion yuan, down 7.15% year-on-year.
From the perspective of specific business segments, GIANT BIOGENE's core brand showed significant differentiation in 2025:
As the absolute mainstay contributing over 80% of revenue, Kefumei achieved sales revenue of 4.470 billion yuan in 2025, a year-on-year decrease of 1.6%.
The financial report pointed out that this was mainly affected by external shocks and intensified price competition in the industry.
Considering the public opinion controversy that erupted in mid-2025, the doubts regarding the normative claims of Kefumei products somewhat weakened consumer trust, causing substantial impact on the sales of this flagship brand.
However, the skincare brand &#34;Keli Jin&#34; still maintained a growth trend, recording revenue of 918 million yuan in 2025, a year-on-year increase of 9.2%.
This was mainly attributed to the active expansion of online channels and the successful launch of the upgraded star product &#34;Da Mo Wang 3.0.&#34;
After experiencing the growing pains of 2025, GIANT BIOGENE has clearly stated its goal to return to growth in 2026.
From the strategic layout revealed in the financial report, GIANT BIOGENE's future core growth points will mainly focus on strengthening the medical beauty business, expanding new ingredient applications beyond collagen, incubating new brands, and expanding across all channels.
The most noteworthy initiative may be the medical beauty business.
Since 2025, GIANT BIOGENE's recombinant type I a1 collagen freeze-dried fibers, recombinant type I a1 collagen, and sodium hyaluronate composite solution products have successively received approval for market launch from the National Medical Products Administration, marking its official entry into the medical beauty market.
The &#34;collagen war&#34; of 2025 was not only a public relations crisis but also a kind of &#34;coming-of-age ceremony&#34; for the industry, exposing GIANT BIOGENE's shortcomings on its rapid journey and prompting it to catch up on product standards and regulations.
In 2026, with three types of medical devices in hand, can GIANT BIOGENE leverage the medical beauty track to successfully turn the tide and regain the rhythm of high growth? The market is watching closely

02367

159849

159837

516500

688363

516930

In mid-2025, a "industry-level public opinion controversy" with Bloomage Biotech pushed GIANT BIOGENE to the forefront. This dispute is not only about the restructuring of collagen

- In mid-2025, a public controversy involving Gigi Biological and Huaxi Biological escalated tensions, impacting Gigi's flagship collagen brand, Kefu Mei, over claims of misrepresented collagen content.  
- Despite a slight revenue decline to 55.18 billion yuan and a net profit drop of 7.15%, Kefu Mei saw a 1.6% decrease in sales, while another brand, Keli King, experienced a 9.2% growth, attributed to online expansion.  
- Looking ahead to 2026, Gigi Biological aims to regain growth through enhanced medical aesthetics business and new product developments, following a year of challenges that revealed shortcomings in product standards.

Wallstreetcn

GIANT BIOGENE

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Bloomage Biotech

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

After the "glass glue war," GIANT BIOGENE shows its first signs of growth anxiety